NEW YORK, Jan. 11, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acorda Therapeutics, Inc. (NASDAQ:ACOR) from April 18, 2016 through November 14, 2017, inclusive (the “Class Period”) of the important January 17, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Acorda investors under the federal securities laws.
To join the Acorda class action, go to http://rosenlegal.com/cases-1242.html or call Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) tozadenant entailed significant undisclosed safety risks; (2) accordingly, the Company had overstated tozadenant’s approval prospects and commercial viability; (3) for the foregoing reasons, the Company had likewise overstated the benefits of the Biotie Acquisition; and (4) as a result of the foregoing, Acorda’s shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1242.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Daniel Sadeh, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



